Rapid Response
To Dig or Not to Dig: A Lethal Question in Atrial Fibrillation?
Abstract
Despite digoxin being considered a class I indication for rate control in many patients with persistent and permanent atrial fibrillation, with or without heart failure, its long-term efficacy and safety remains uncertain. Well-designed, multicenter, randomized clinical trials are necessary to clarify the safety profile of a drug daily used in thousands of patients.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
